2027 ICD-10-CM Diagnosis Code D07.5Carcinoma in situ of prostate
ICD-10-CM Codes›C00–D49›D00-D09›D07
- Billable — Valid for Submission
- Chronic Condition
D07.5 is a billable ICD-10-CM diagnosis code for carcinoma in situ of prostate. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 715 through 716, 722 through 724. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Male reproductive system cancers - prostate.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Carcinoma in situ of prostate
- Carcinoma in situ of prostatic ducts
- High grade prostatic intraepithelial neoplasia
- Prostatic intraepithelial neoplasia
- Prostatic intraepithelial neoplasia and adjacent atypia
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to D07.5: its own notes plus those printed at D07, block D00-D09, and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Includes
Further defines, or gives examples of, the content of the category.
- Bowen's disease
- erythroplasia
- grade III intraepithelial neoplasia
- Queyrat's erythroplasia
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Prostatic intraepithelial neoplasia III (PIN III)
- Severe dysplasia of prostate
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name D07.5, its category, or a range that includes it.
Applicable To 1
These notes mention D07.5.
Excludes1 2
These codes carry an Excludes1 note naming D07.5: they are not reported together with it, unless the two conditions are unrelated.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Dysplasia See Also: Anomaly;
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Grade III Prostatic Intraepithelial Neoplasia
high grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.
Table of NeoplasmsClinical
Patient EducationClinical
Prostate Cancer
Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen.
The full article covers:
- What is prostate cancer?
- What causes prostate cancer?
- Who is more likely to develop prostate cancer?
- What are the symptoms of prostate cancer?
- What are prostate tests and how is prostate cancer diagnosed?
- What are the treatments for prostate cancer?
- Can prostate cancer be prevented?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D07.5 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D07.5Overview
What is the ICD-10 code for carcinoma in situ of prostate?
The ICD-10-CM code for carcinoma in situ of prostate is D07.5 (sometimes written as D075). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is D07.5 (Carcinoma in situ of other and unspecified genital organs) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report carcinoma in situ of prostate on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does D07.5 group to?
When carcinoma in situ of prostate is the principal diagnosis on an inpatient stay, it groups to MS-DRG 716, 723, 724, 715, 722, with relative weights from 0.5709 to 2.2896 depending on complications. Higher weights mean higher Medicare reimbursement.
Can D07.5 be reported with a code from N42.3?
Not as a rule. The Excludes1 note on D07.5 lists "dysplasia (mild) (moderate) of prostate (N42.3-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What is the ICD-9 equivalent of D07.5?
Under the General Equivalence Mappings, carcinoma in situ of prostate converts to ICD-9-CM 233.4 (ca in situ prostate). The mapping is a direct match.
